ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.61), $0.12 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $22.67 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.